Please login to the form below

Not currently logged in
Email:
Password:

UK/Russian pharma firm launches

Global pharmaceutical company, Pro Bono Bio, has launched today with funding from UK-based Celtic Pharma and the state-owned Russian Corporation of Nanotechnologies (RusNano)

Global pharmaceutical company, Pro Bono Bio, has launched today with funding from UK-based Celtic Pharma and the state-owned Russian Corporation of Nanotechnologies (RusNano).

The company said it intends to support a 'unique humanitarian mission' with products to be priced in different areas based on the region's ability to pay.

Free drug donations will be available to countries in Africa based on the success of products sold Western Europe.

The launch of Pro Bono Bio comes at the same time as UK Prime Minister David Cameron's visit to Russia.

He said: "This is a great example of UK/Russia collaboration at the cutting edge of R&D. It demonstrates how British businesses can work together with their Russian counterparts to expand into new areas, creating jobs and prosperity here in the UK."

As part of the company's development, Pro Bono Bio said it intends to build a manufacturing plant in the UK. A further facility is also planned for Moscow.

The company is to launch its first product Flexiseq, a nanotechnology based treatment for osteoarthritis, in the UK today, with further plans to release drugs for skin disorders in the coming months.

Other pipeline products for the company include blood factors for the treatment of haemophilia as well as antibiotics for the treatment of infections such as Clostridium difficile, MRSA and tuberculosis.

12th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics